Related references
Note: Only part of the references are listed.A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2007)
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy
Ofer Yossepowitch et al.
EUROPEAN UROLOGY (2007)
Setting the bar in phase II trials: The use of historical data for determining go/no go decision for definitive phase III testing
Andrew J. Vickers et al.
CLINICAL CANCER RESEARCH (2007)
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations
Dennis C. Turk et al.
PAIN (2006)
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
Mark T. Fleming et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel
Peter Jochen Olbert et al.
ANTI-CANCER DRUGS (2006)
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator
Jacob N. Beverage et al.
CANCER BIOLOGY & THERAPY (2006)
Androgen-deprivation therapy as primary treatment for localized prostate cancer - Data from cancer of the prostate strategic urologic research endeavor (CaPSURE)
J Kawakami et al.
CANCER (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Prostate cancer clinical trial end points: RECISTing a step backwards
HI Scher et al.
CLINICAL CANCER RESEARCH (2005)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
HI Scher et al.
ENDOCRINE-RELATED CANCER (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Intermittent chemotherapy in metastatic androgen-independent prostate cancer
TM Beer et al.
BRITISH JOURNAL OF CANCER (2003)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial
MA Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
O Smaletz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Clinical states in prostate cancer: Toward a dynamic model of disease progression
HI Scher et al.
UROLOGY (2000)
Share Paper
